共查询到20条相似文献,搜索用时 375 毫秒
1.
癌症患者红细胞调控IL-8的意义 总被引:4,自引:1,他引:3
[目的]探讨癌症患者红细胞在血液中调控白细胞分泌IL-8的规律。[方法]将新鲜血浆0.3ml加入0.2ml全血细胞悬液:包括红细胞和白细胞或0.2ml白细胞悬液中,混匀37℃水浴1h。用免疫酶联法测定IL-8含量。[结果]在血液免疫功能变化中,红细胞能调控白细胞分泌IL-8含量,正常人(21例)红细胞IL-8吸附率(0.66±0.16)明显高于遗传性球形红细胞增高症(1例)(0.31)和肿瘤患者(15例)红细胞IL-8吸附率(-0.04±0.55),P<0.01。[结论]红细胞在血液中调控白细胞分泌IL-8含量水平中扮演极其重要的角色,肿瘤患者红细胞趋化因子受体调控活性明显低下。 相似文献
2.
高强度聚焦超声治疗肝癌后免疫功能的变化 总被引:9,自引:0,他引:9
目的了解高强度超声聚焦热疗(HIFU)治疗后原发性肝癌患者的免疫功能变化情况.方法应用FEP-BY01型肿瘤超声治疗机对42例原发性肝癌患者进行治疗.分别取HIFU治疗前和HIFU治疗后4周外周血10 ml,检测T细胞亚群:CD4、CD8、CD4/CD8;Th细胞因子:IFN-γ、IL-2、IL-4、Il-10.结果 42例肝癌患者治疗前和治疗后CD4、CD8 T细胞百分数、CD4/CD8比值分别为(29.5±4.8)%和(38.2±5.1)%(P<0.05);30.2±6.4%和24.4±3.7% (P<0.05);0.9±0.3和1.7±0.2(P<0.01);治疗前和治疗后IL-2、IFN-γ、IL-4、IL-10含量(pg/ml)分别为93.5±28.3和110.5±24.2(P<0.05);73.2±18.6和92.8±20.1(P<0.05);82.3±14.2和60.2±11.3(P<0.01);74.8±21.9和56.2±19.1(P<0.01).结论经HIFU治疗后肝癌患者的CD4 T细胞百分数和CD4/CD8比值明显升高,CD8 T细胞百分数下降;IL-2和IFN-γ水平明显升高,而IL-4和IL-10水平明显下降.应用HIFU技术治疗原发性肝癌可以改善患者体内的细胞免疫功能和Th1向Th2漂移的状态. 相似文献
3.
脐血血浆中IL-3、IL-12、TNF-α含量的测定 总被引:1,自引:0,他引:1
目的:测定脐血血浆中IL-3、IL-12、TNF-α的含量,了解脐血造血干/祖细胞(HSC/HPC)的造血微环境。方法:收集20份脐血,常规分离血浆。结果:20份脐血血浆TNF-α含量为(29.146±17.450)pg/mL,明显低于成人外周血(P<0.0001),IL-3、IL-12含量分别为(44.660±9.879)pg/mL和(1572.361±785.743)pg/mL,均显著高于成人外周血(P<0.01)。结论:脐血中富含各种造血生长因子,有良好的造血微环境,为移植后全面持久的造血重建奠定了基础。 相似文献
4.
人IL-2、sIL-2R、IL-8酶联免疫测定在癌症标本检测中的应用 总被引:1,自引:0,他引:1
本文采用酶联免疫法测定癌症病人血浆IL-2、sIL-2R、IL-8含量的变化,探讨与肿瘤的发生机制,疗效观察及愈后估计.本研究发现,良性垂体瘤组IL-2(12.75±4.40 pg/ml)、sIL-2R(92±46.92 pg/ml)、IL-8(36.38±3.06 pg/ml)与正常对照组IL-2(15.00±4.20 pg/ml)、sIL-2R(70±45.01 pg/ml)、IL-8(30.02±4.60 pg/ml)相比,未见明显改变(P>0.05).而胶质瘤、胃癌、肺癌组病例IL-2、sIL-2R含量有明显改变(P<0.05),肺癌组病例IL-8含量明显增高(P<0.05).胃癌组手术前IL-2(8.18±3.21 pg/ml)、sIL-2R(178.36±50.21 pg/ml)与癌肿全切后IL-2(17.34±5.10 pg/ml)、sIL-2R(128.31± 相似文献
5.
癌细胞激活血液免疫反应路线图初步研究 总被引:7,自引:1,他引:7
[目的]建立IL-8、IL-6和趋化因子受体DARC(Fy6)测定方法,用于癌细胞激活血液免疫反应路线图理论研究.[方法]用IL-8、IL-6免疫酶联和Fy6流式细胞仪测定法,建立血液免疫反应路线图实验体系.癌细胞(S180,5×106/ml)或生理盐水加入新鲜抗凝全血或红细胞、白细胞、血浆(或生理盐水)中,37℃水浴1h后观察结果.[结果]癌细胞能激活血液免疫反应路线图实验体系,在癌细胞加入全血细胞组,IL-8(351.6pg/ml)高于生理盐水加入全血细胞组IL-8水平(<0.5pg/ml),在癌细胞加入全血细胞组红细胞Fy6水平(28.85)低于生理盐水加入全血细胞组红细胞上Fy6水平(45.80).在癌细胞加入全血细胞组,IL-8和IL-6激活指数(2.86或1)高于癌细胞加入白细胞组(0.36或0.25).在癌细胞加入全血细胞组,IL-8增值水平(69.19±37.53pg/ml)高于癌细胞加入白细胞组IL-8增值水平(19.85±11.53pg/ml).[结论]红细胞和补体在血液免疫反应(如IL-8、IL-6)调控中是一个很重要的角色,客观存在血液免疫反应路线图网络. 相似文献
6.
目的:探讨IL-12通过诱导肝癌微环境中NK细胞活化诱导抗肿瘤的效果。方法:NOD/SCID小鼠皮下注射肝癌HepG2细胞,成瘤后腹腔注射人外周血淋巴细胞(peripheral blood lymphocyte,PBL),建立HCC-huPBL荷瘤小鼠模型。将荷瘤小鼠随机分为IL-12组和PBS对照组,瘤内注射IL-12后,观测荷瘤小鼠瘤体积、体重、一般状况的变化,IL-12瘤内注射后第30天ELISA法检测荷瘤小鼠肝癌组织微环境中IL-12、INF-γ含量以及小鼠外周血中天门冬氨酸氨基转移酶(aspartate amin-otransferase,AST)及谷丙转氨酶(alanine aminotransferase,ALT)的含量,免疫组化法检测IL-12治疗后肝癌微环境中NK细胞活化性受体NKG2D、NKp44、NKp30、NKp46,以及抑制性受体KIR2DL3/CD158b、NKG2A/CD159a的表达。结果:第12、18、24、30天IL-12组荷瘤小鼠瘤体积均小于PBS组[(594.47±205.51)vs(832.10±187.49)mm3,(963.61±427.95)vs(1 350.87±468.23)mm3,(1 285.02±368.56)vs(1 975.49±655.54)mm3,(1 903.64±471.34)vs(2 568.77±784.68)mm3,均P<0.05]。IL-12组小鼠肝癌组织中IL-12与INF-γ的表达水平均明显高于PBS组[(2.96±1.02)vs(1.35±0.75)pg/ml,(12.26±4.11)vs(7.81±3.46)pg/ml,均P<0.05]。IL-12组与PBS组相比,血清ALT水平第7天显著升高[(73.85±10.71)vs(41.73±13.13)U/L;P<0.05],第14天达到高峰。IL-12组治疗后肝癌组织中NK细胞活化性受体NKG2D、NKp44、NKp30的表达较PBS组高(P<0.05),NKp46的表达未见明显升高;而NK细胞抑制性受体CD158b和CD159a表达较PBS组低(P<0.05)。结论:肝癌模型小鼠瘤体内IL-12注射可上调瘤组织内NK细胞活化性受体、IL-12、IFN-γ的表达,下调抑制性受体的表达,从而抑制小鼠模型中肿瘤的生长。 相似文献
7.
目的探讨血浆循环DNA载量对原发性肝癌的临床诊断价值。方法采用real time-PCR的方法,检测原发性肝癌患者确诊前及确诊后血浆循环DNA载量。结果原发性肝癌患者血浆循环DNA载量确诊后[(63.1±16.3)ng/ml]显著高于确诊前(P<0.01),确诊前6个月的血清循环DNA载量[(28.3±12.7)ng/ml]显著高于确诊前12个月、18个月和24个月的;原发性肝癌患者发生淋巴结转移者的血浆DNA载量[(79.3±13.7)ng/ml]显著高于未发生淋巴结转移者[(52.1±12.5)ng/ml](P<0.01)。结论 Real time-PCR检测血浆循环DNA,有可能成为原发性肝癌早期筛查和诊断的一个新的临床标准。 相似文献
8.
目的 探讨人骨髓来源的间充质干细胞(BMSC)在体外对外周血Th17细胞及IL-17的调节作用.方法 用淋巴细胞分离液以密度梯度离心法分离3例急性髓系白血病(AML)、3例急性淋巴细胞白血病(ALL)、1名健康人BMSC及健康人外周血单个核细胞(PBMC)并传代培养;酶联免疫吸附法(ELISA)检测培养上清中的IL-17;流式细胞术检测共培养的健康人外周血中Th17细胞所占百分比.结果 AML患者BMSC与健康人PBMC共培养后,上清中IL-17表达水平为(292.32±37.25) pg/ml,与健康人BMSC与PBMC共培养上清中的IL-17水平[(169.64±17.47)pg/ml]相比,差异有统计学意义(P< 0.01);ALL患者的BMSC与PBMC共培养后,上清中的IL-17表达水平为(159.89±23.71)pg/ml,与健康人BMSC与PBMC共培养上清的差异无统计学意义(P>0.05).健康人、ALL和AML患者BMSC与健康人PBMC共培养体系中Th17细胞的百分比分别为(10.13±2.19)%、(13.77±4.04)%、(21.53±5.05)%,AML患者与健康人间差异有统计学意义(P<0.01),ALL患者与健康人间差异无统计学意义(P>0.05).结论 AML患者BMSC促进外周血CD4+T细胞分化产生Th17细胞,AML患者BMSC可能在免疫抑制调节中发挥作用. 相似文献
9.
目的:研究围术期肺癌患者CD4+/CD8+T细胞与TGF-β、IL-4、IL-6的含量变化及临床意义。方法分别采用流式细胞术(Flow cytometry,FCM)及酶联免疫吸附法(ELISA)检测20例肺癌患者手术前后和10例正常对照者CD4+T、CD8+T细胞比例及细胞因子TGF-β、IL-4和IL-6的含量。结果20例肺癌患者术前CD4+T、CD8+T细胞比例分别为(46.26±4.26)%、(43.15±5.18)%,术后5天分别为(44.30±4.25)%、(39.80±2.53)%;肺癌患者术前血清中TGF-β、IL-4、IL-6的含量分别为(240.51±46.37)pg/mL、(19.85±2.52) pg/mL、(129.28±33.06) pg/mL,术后5天分别为(210.79±36.94) pg/mL、(17.37±2.57) pg/mL、(107.28±27.83) pg/mL。两组之间差异均有统计学意义( P<0.05)。结论围术期肺癌患者的免疫状态呈先抑制后恢复,监测围术期CD4+/CD8+T细胞与TGF-β、IL-4、IL-6的含量变化对肿瘤患者病情监测及预后判断具有重要意义。 相似文献
10.
氩氦冻融的肺癌细胞对人外周血单个核细胞免疫功能的影响 总被引:2,自引:0,他引:2
[目的]观察氩氦冻融的小细胞肺癌细胞NCI-H446对正常人外周血单个核细胞免疫功能的影响。[方法]分离正常人外周血单个核细胞,与氩氦冻融的小细胞肺癌细胞NCI-H446混合培养,设一个空白对照组,培养过程中隔天加入IL-210U,分别在第3、7、14d检测培养上清液中IL-12、IL-10含量及NK细胞、CTL细胞的杀伤活性。[结果]氩氦冻融的肺癌细胞NCI-H446与PBMC混合培养后,第3、7d时,培养上清液中IL-12含量分别为71.8±19.1pg/ml,106.2±13.6pg/ml,对照组IL-12含量为38.5±8.4pg/ml,40.8±8.3pg/ml,试验组较对照组明显升高(P<0.05),在第14d时试验组与对照组IL-12表达相当。IL-10的表达在试验组与对照组之间始终未发现明显差异。试验组NK细胞、CTL细胞的杀伤活性在14d内均明显高于对照组(P<0.05)。[结论]氩氦冻融的肺癌细胞可以上调PBMC对IL-12的表达,而对IL-10的表达无影响,同时可明显增强NK细胞和CTL活性。 相似文献
11.
IL-4, IL-17 and CD163 Immunoexpression and IL-6 Gene Polymorphism in Chronic Hepatitis C Patients and Associated Hepatocellular Carcinoma
下载免费PDF全文
![点击此处可从《Asian Pacific journal of cancer prevention》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Tarek AboushoushaMarine EmadGina RizkKhaled RagabOlfat HammamRabab FouadNoha Said Helal 《Asian Pacific journal of cancer prevention》2021,22(4):1105-1113
Objective: To assess the expression of IL-4, IL-17 and CD-163 as well as study of IL6-572 C/G gene polymorphism in chronic HCV and HCC on top of HCV. Methods: Sixty HCC specimens and 60 adjacent hepatic tissue with HCV of different grades of necro-inflammation and different stages of fibrosis. In addition to 55 HCV, 60 HCC and 50 healthy venous blood samples for evaluation of IL6-572 C/G gene polymorphism. Results: high expression of IL-4, IL-17 and CD163 in higher grades of activity, late stages of fibrosis and higher degrees of steatosis of HCV. IL-4 and CD163 showed higher expression in advanced grades of HCC, while IL-17 more expressed in lower grades. No significant difference in IL6-572 C/G gene polymorphism among studied groups regarding G/C, G/G, C/C frequencies or G and C allele’s frequencies. Conclusion: IL-4, IL-17 and CD163 were associated with HCV severity. Their expression in HCC suggests their important role in HCC development. Blocking of these proteins may be a good target to control inflammation in HCV and can hinder progression to cirrhosis then to HCC. On the other hand, IL6-572 promoter gene polymorphism is neither associated with HCV infection nor with HCC development and its progression. 相似文献
12.
目的: 探讨不同期别的鼻咽癌(nasopharyngeal carcinoma,NPC)患者血清中CD62p、IL-6、IL-8的表达与肿瘤分期及预后的关系.方法: 采用酶联免疫吸附法(ELISA)检测83例病理确诊为NPC的各期放疗前患者血清与17例正常人血清中CD62p、IL-6、IL-8的表达,分析各指标的表达与肿瘤分期及预后的关系.结果: CD62p、IL-6、IL-83个指标在NPC患者血清中的表达明显高于正常人群(P<0.01);与患者的年龄和性别无关(P>0.05);与肿瘤的TNM分期及肿瘤临床分期呈正相关(P<0.05);且CD62p、IL-6、IL-8 3个指标间存在正相关性(P<0.05).结论: CD62p、IL-6、IL-83个指标在各期鼻咽癌患者血清中高表达与鼻咽癌的TNM分期及肿瘤临床分期呈正相关,可以作为NPC肿瘤转移的前瞻性指标. 相似文献
13.
目的研究食管癌组织中共刺激分子CD80、CD86 mRNA的表达以及与TGF-β1、IL-10 mRNA表达水平的关系,探讨食管癌组织中树突细胞免疫功能降低及食管癌发生免疫逃逸的原因。方法应用逆转录聚合酶链反应(PT-PCR)技术,检测62例食管癌患者癌组织中CD80、CD86及TGF-β1、IL-10 mRNA的表达。以16例正常食管黏膜组织作为对照。结果食管癌组织中,CD80、CD86 mRNA的表达分别为0.631±0.212和0.530±0.210,均低于正常食管黏膜组织(P值分别为0.038和0.0002);Ⅰ、Ⅱ期患者高于Ⅲ、Ⅳ期患者(CD80:P=0.029;CD86:P=0.045);高中分化者高于低分化者(CD80:P=0.046;CD86:P=0.044)。食管癌组织中,TGF-β1、IL-10的mRNA表达分别为1.273±0.086和1.182±0.073,均高于正常食管黏膜组织(P值均为0.0001),且分别与CD80、CD86的mRNA表达呈负相关(P=0.0001)。结论食管癌组织中,CD80、CD86 mRNA的表达降低与TGF-β1、IL-10 mRNA的高表达呈负相关,癌组织内TGF-β1、IL-10 mRNA的表达增强是导致CD80、CD86 mRNA表达降低的重要影响因素,可能是引起DC功能缺陷和食管癌细胞发生免疫逃逸的原因之一。 相似文献
14.
目的 检测白细胞介素(IL)-17+CD4+T(Th17)细胞和IL-17+CD8+ T(Tc17)细胞在肺癌患者外周血中的表达水平,探讨二者在肺癌免疫中的作用及临床意义.方法 采用流式细胞术(FCM)检测60例肺癌患者及40例健康对照者外周血中Th17和Tc17细胞占CD;T细胞的比例.结果 肺癌组外周血中Th17细胞[(1.795±0.623)%]和Tc17细胞[(0.865±0.357)%]比例分别高于对照组[(1.405±0.256)%、(0.640±0.204)%],(t=28.944,P< 0.001;t=14.051,P< 0.001).两组内Th17细胞与Tc17细胞的表达水平均呈正相关(肺癌组r=0.770,P<0.05;对照组r=0.532,P<0.05).Th7细胞和Tc17细胞表达均与临床分期有关(F值分别为4.882、3.633,均P<0.05),但与病理类型无关(均P>0.05).结论 肺癌患者体内Th17细胞和Tc17细胞表达升高,二者可能参与了肺癌的发生、发展;Th17与Tc17细胞的表达水平可作为评价肺癌患者免疫功能状态的新指标,能为病情监测提供参考. 相似文献
15.
Melina Helbling Anne Lukesch Aladin Haimovici Eva Karamitopoulou Martin D. Berger Marion H?drich Makhmud Mallaev Beat Schnüriger Viktor H. Koelzer Heather Dawson Markus Borner Rupert Langer Robert Rosenberg Ulrich Nitsche Daniel Inderbitzin Alessandro Lugli Mario P. Tschan Inti Zlobec 《Oncotarget》2014,5(13):4671-4682
IL-23 is a heterodimeric cytokine involved in inflammatory diseases; its role in cancer progression is controversial. Here we analyse the expression of IL-23 subunits (p40 and p19) and IL-23R in colorectal cancer with regard to disease progression, clinical-pathological and molecular aspects. Immunohistochemistry for IL-23p19, IL-23p40, IL-23R and CD8 was performed on a multi-punch tissue microarray of 195 colorectal cancers (cohort 1), matched normal tissue, adenoma and lymph node metastases. Results were compared with clinical-pathological features and CD8+ T-cell counts, then validated on two patient cohorts (cohort 2: n=341, cohort 3: n=139). Cytoplasmic/membranous expression of IL-23 (p19 and p40 subunits) and IL-23R, respectively were over-expressed in carcinomas versus adenomas and normal tissues (p<0.0001) but were reduced in lymph node metastases (p<0.0001). Nuclear IL-23p19 expression was observed in 23.1% and was associated with early TNM stage (p=0.0186), absence of venous (p=0.0124) and lymphatic invasion (p=0.01493), favorable survival (p=0.014) and absence of distant metastasis (p=0.0146; specificity: 100%). This unexpected cellular localization was confirmed by cell fractionation. The beneficial effect of nuclear IL-23p19 was restricted to tumours with CD8+ high counts. Results were validated on Cohorts 2/3. This multicenter study underlines the possible CD8+ dependency and beneficial effect of nuclear IL-23p19 on overall patient survival. 相似文献
16.
目的探讨乳腺癌演变中新生血管表达状况,旨在选择乳腺癌发生发展中新生血管的特异性标记物。方法采用免疫组化(SP)法,分别以CD105、FⅧ、CD31、CD34为标记,对100例乳腺不同病变组织,包括乳腺导管上皮不典型增生(ADH)、导管内癌(DCIS)、微浸润导管癌(MDC)各20例,40例非特殊类型浸润型导管癌(IDC,NOS),计算微血管密度(MVD)。结果ADH、DCIS、MDC和IDC(NOS)中,CD105标记的MVD分别为8.25±5.78、10.05±4.23、25.35±7.62和37.33±5.86,FⅧ标记的MVD分别为10.60±8.99、16.60±3.47、16.90±5.62和17.90±5.62,CD31标记的MVD分别为16.80±3.90、19.40±4.58、20.74±6.67和22.74±6.67,CD34标记的MVD分别为14.40±12.82、25.20±5.39、26.32±4.89和40.32±4.89,仅CD105标记的MVD各组间两两比较差异有统计学意义(P〈0.05)。结论CD105标记MVD用来评估乳腺癌发生发展中的新生血管表达,可能更具价值,这将为今后抗血管生成的治疗提供理论依据。 相似文献
17.
Nathalie Renard Nobuyuki Harada Evelyne Callet-Bauchu Atsushi Miyajima Valrie Duvert Jacques Banchereau Sem Saeland 《Leukemia research》1997,21(11-12)
The present study describes two novel cell lines, DUNATIS and SILVANUS, established from B lineage acute lymphoblastic leukemia patients. Respectively, DUNATIS and SILVANUS display an early pre-B cell and a pre-B cell phenotype. Spontaneous DNA replication of both cell lines was strongly inhibited by IL-4. This effect was directly mediated by IL-4 and exerted through the CD124 IL-4 receptor chain. Notably, IL-4 was associated with rapid cell death and reduction of cellularity in DUNATIS, whereas these parameters were considerably less pronounced and only observed after longer-term exposure of the SILVANUS cells to IL-4. In addition to these differences, although both cell lines expressed FES oncoprotein, a 100 kDa protein associated with FES was strikingly found to be tyrosine-phosphorylated in response to IL-4 exclusively in DUNATIS cells.These data demonstrate that IL-4 displays heterogenous effects on leukemic B cell precursors responsive to inhibition of DNA synthesis via IL-4 mediated engagement of the CD124 receptor chain. The present findings may be of use for appreciation of the effects of IL-4 in B lineage ALL, and the novel cell lines could represent a model for further identification of target molecules in IL-4 signalling. 相似文献
18.
Intracavitary VEGF,bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma 总被引:7,自引:1,他引:6
Salmaggi A Eoli M Frigerio S Silvani A Gelati M Corsini E Broggi G Boiardi A 《Journal of neuro-oncology》2003,62(3):297-303
Intracavitary levels of VEGF, bFGF, IL-8 and IL-12 were evaluated by ELISA in 45 patients, 7 with recurrent anaplastic astrocytoma (rAA), 12 with glioblastoma (GBM) and 26 with recurrent glioblastoma (rGBM). In 25 patients plasma levels of the molecules were also quantitated. Twenty-three healthy controls were also studied for plasma concentrations of the same molecules.Plasma levels of VEGF (mean 33.89 ± 6.71pg/ml) and bFGF (mean 11.1 ± 3.24pg/ml) were higher in patients than in controls (mean 16.78 ± 3.7pg/ml for VEGF, mean 0.21 ± 0.09pg/ml for bFGF) (p = 0.04 and p = 0.001, respectively) while plasma IL-12 levels were lower (mean 45.6 ± 1.5pg/ml in patients, mean 79.7 ± 1.3pg/ml in controls) (p = 0.009).Intracavitary VEGF levels were 5–53.307 fold higher (mean 90,900 ± 24,789pg/ml) than in the corresponding plasma. Also IL-8 concentrations were higher in intracavitary fluid (mean 6,349.76 ± 1,460.93pg/ml) than in plasma (mean 43.44 ± 24.82pg/ml). Maximum VEGF levels were found in tumor fluid of recurrent glioblastoma patients (mean 147,678 ± 39,903pg/ml), intermediate levels in glioblastoma patients (mean 20,322 ± 11,892pg/ml) and lower levels in rAA patients (mean 9,111 ± 5,789pg/ml). The data also suggest that higher intracavitary levels of VEGF and IL-8, and lower IL-12 levels, may be correlated with shorter adjunctive survival times, but more data will need to be collected to establish this correlation clearly. 相似文献
19.
目的 探讨CD80、CD86和CD137L基因联合表达增强宿主细胞毒性T淋巴细胞(CTL)杀伤活性的机制.方法 BAL B/c小鼠随机分为5组,A组接种H22-Wt细胞,B组接种H22-neo细胞,C组接种H22-CD80/CD86+细胞,D组接种H22-CD137L+细胞,E组接种H22-CD80/CD86/CD137L+细胞.分别于第14、35、56和84天,每组每次随机选取2只小鼠处死取材.原位末端标记法(TUNEL)和DNA ladder法检测脾淋巴细胞凋亡.电泳迁移率法(EMSA)检测T细胞核因子KB(NF-KB)活性.结果 TUNEL检测结果显示,接种后第14天,A、B组脾淋巴细胞即出现大量凋亡,D组凋亡虽然较A、B组明显减少,但仍远高于C、E组.随接种时间推移,C组脾淋巴细胞凋亡逐渐增多,而E组这一趋势不明显,至第84天,C组和E组的脾淋巴细胞凋亡指数分别为30.8±9.2和14.4±4.5.DNA ladder检测结果显示,接种后第14、35、56和84天,C组和E组均检测出典型阳性结果,其中以C组第35、56和84天凋亡最明显.EMSA检测结果显示,A、B组T细胞NF-KB活性很低,D组显著高于A、B组,C、E组则显著高于A、B和D组.随着接种时间推移,E组NF-KB活性一直维持较高水平,而C组呈现逐渐下降趋势,至第84天,C组和E组的T细胞NF-KB活性分别为14.01±1.04和41.16±5.78.结论 H22-CD80/CD86/CD137L+变异株接种荷瘤鼠后,CD28信号和CD137信号的协同作用可显著增强活化T细胞NF-KB活性,这可能是CD80、CD86和CD137L基因联合表达显著增强宿主CTL杀伤活性的机制之一. 相似文献